newsfilter
← Latest News
GlobeNewswire·

SAB BIO to Participate in Upcoming Investor Conferences

  • SAB Biotherapeutics Inc. (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the Jefferies Global Healthcare Conference on November 16, 2026, in London, UK.
  • The company confirmed participation in the UBS Global Biopharma Conference on November 17, 2026, in London, UK, with a fireside chat featuring Reich.
  • SAB Biotherapeutics management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026, in Coral Gables, FL, where Reich will participate in a fireside chat.
  • One-on-one meetings with SAB Biotherapeutics management are scheduled for the Citi Global Healthcare Conference on December 2, 2026, in Miami, FL.
  • SAB BIO is a clinical-stage biopharmaceutical company developing human immunoglobulin G (hIgG) therapies using transchromosomic cattle technology to treat immune disorders without human donors.
  • The company's lead candidate, SAB-142, is a fully human anti-thymocyte immunoglobulin (hATG) targeting autoimmune type 1 diabetes (T1D) with the goal of delaying onset or preventing progression in Stage 3 patients.
  • SAB-142 is currently being evaluated in the registrational Phase 2b SAFEGUARD study for newly diagnosed Stage 3 T1D patients.
  • The investigator-led Phase 3 PRISE-hATG study is evaluating SAB-142 for individuals diagnosed with Stage 3 T1D up to two years prior.
  • Interested parties can arrange meetings through conference representatives or access live/replay webcasts via the Investors & Media section of www.sab.bio.
Company
SAB Biotherapeutics, Inc.
Keywords
Nasdaq:SABS, SAB Biotherapeutics, Inc.